Mattheolabakis G - Search Results

1

Targeting endothelial permeability in the EPR effect.

Lahooti B, Akwii RG, Zahra FT, Sajib MS, Lamprou M, Alobaida A, Lionakis MS, Mattheolabakis G, Mikelis CM. Lahooti B, et al. Among authors: mattheolabakis g. J Control Release. 2023 Sep;361:212-235. doi: 10.1016/j.jconrel.2023.07.039. Epub 2023 Aug 8. J Control Release. 2023. PMID: 37517543 Review.

2

Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles.

Lahooti B, Akwii RG, Patel D, ShahbaziNia S, Lamprou M, Madadi M, Abbruscato TJ, Astrinidis A, Bickel U, Al-Ahmad A, German NA, Mattheolabakis G, Mikelis CM. Lahooti B, et al. Among authors: mattheolabakis g. J Pharmacol Exp Ther. 2023 Apr;385(1):35-49. doi: 10.1124/jpet.122.001384. Epub 2023 Feb 6. J Pharmacol Exp Ther. 2023. PMID: 36746610 Free PMC article.

3

Murine Dermal Lymphatic Endothelial Cell Isolation.

Akwii RG, Lamprou M, Georgomanoli M, Plevriti A, Marazioti A, Mouzaki A, Mattheolabakis G, Mikelis CM. Akwii RG, et al. Among authors: mattheolabakis g. J Vis Exp. 2023 Jul 21;(197). doi: 10.3791/65393. J Vis Exp. 2023. PMID: 37590510

4

Stable Dual miR-143 and miR-506 Upregulation Inhibits Proliferation and Cell Cycle Progression.

Shrestha A, Lahooti B, Hossian AKMN, Madadi M, Mikelis CM, Mattheolabakis G. Shrestha A, et al. Among authors: mattheolabakis g. Int J Mol Sci. 2024 Apr 17;25(8):4432. doi: 10.3390/ijms25084432. Int J Mol Sci. 2024. PMID: 38674017 Free PMC article.

5

Lyophilized liposomal formulation of a peptidomimetic-Dox conjugate for HER2 positive breast and lung cancer.

Sonju JJ, Shrestha P, Dahal A, Gu X, Johnson WD, Zhang D, Muthumula CMR, Meyer SA, Mattheolabakis G, Jois SD. Sonju JJ, et al. Among authors: mattheolabakis g. Int J Pharm. 2023 May 25;639:122950. doi: 10.1016/j.ijpharm.2023.122950. Epub 2023 Apr 12. Int J Pharm. 2023. PMID: 37059241

6

Chlorotoxin and Lung Cancer: A Targeting Perspective for Drug Delivery.

Shrestha A, Lahooti B, Mikelis CM, Mattheolabakis G. Shrestha A, et al. Among authors: mattheolabakis g. Pharmaceutics. 2022 Nov 26;14(12):2613. doi: 10.3390/pharmaceutics14122613. Pharmaceutics. 2022. PMID: 36559106 Free PMC article.

7

Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research.

Cerrato A, Mattheolabakis G, Spano D. Cerrato A, et al. Among authors: mattheolabakis g. Front Oncol. 2022 Feb 2;12:842114. doi: 10.3389/fonc.2022.842114. eCollection 2022. Front Oncol. 2022. PMID: 35186769 Free PMC article. No abstract available.

8

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.

Lahooti B, Poudel S, Mikelis CM, Mattheolabakis G. Lahooti B, et al. Among authors: mattheolabakis g. Front Oncol. 2021 Dec 9;11:705634. doi: 10.3389/fonc.2021.705634. eCollection 2021. Front Oncol. 2021. PMID: 34956857 Free PMC article. Review.

9

Oral Delivery of Nucleic Acids with Passive and Active Targeting to the Intestinal Tissue Using Polymer-Based Nanocarriers.

Poudel S, Napit PR, Briski KP, Mattheolabakis G. Poudel S, et al. Among authors: mattheolabakis g. Pharmaceutics. 2021 Jul 13;13(7):1075. doi: 10.3390/pharmaceutics13071075. Pharmaceutics. 2021. PMID: 34371766 Free PMC article.

10

Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance.

Hossian AKMN, Zahra FT, Poudel S, Abshire CF, Polk P, Garai J, Zabaleta J, Mikelis CM, Mattheolabakis G. Hossian AKMN, et al. Among authors: mattheolabakis g. Sci Rep. 2021 Mar 22;11(1):6520. doi: 10.1038/s41598-021-85930-y. Sci Rep. 2021. PMID: 33753779 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page